ArticleCureus2025
Tumor Lysis Syndrome Following Endoscopic Retrograde Cholangiopancreatography With Stent Placement in a Patient With Cholangiocarcinoma: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor lysis syndrome (TLS) is an oncological emergency commonly associated with hematologic malignancies and aggressive chemotherapy. Its occurrence following endoscopic retrograde cholangiopancreatography (ERCP) with stent placement in patients with cholangiocarcinoma is exceedingly rare, with only a handful of cases reported in the literature. This report discusses a unique case of TLS occurring after ERCP in a patient with cholangiocarcinoma, highlighting the clinical challenges and the need for heightened awareness among clinicians. Herein, we present the case of a 58-year-old female patient with a diagnosis of cholangiocarcinoma who developed TLS following ERCP with stent placement. The patient initially underwent the procedure to relieve biliary obstruction, a common palliative intervention in cholangiocarcinoma cases. Within 24 hours post-procedure, the patient exhibited signs of acute renal failure, hyperkalemia, hyperphosphatemia, and hypocalcemia, consistent with TLS. Prompt recognition and aggressive management, including hydration, electrolyte correction, and renal support, were crucial in stabilizing the patient. Despite prompt recognition and aggressive management, including hydration, electrolyte correction, and renal support, the patient unfortunately passed away 24 hours later. This tragic outcome underscores the critical importance of early recognition and intervention, as well as the need for awareness of this rare but possible complication. This case highlights the rare but serious risk of TLS following ERCP in patients with cholangiocarcinoma. Clinicians should be aware of this potential complication, especially in patients with a high tumor burden or those undergoing palliative procedures. Early recognition and intervention are paramount in improving patient outcomes. Further studies are needed to better understand the mechanisms and predisposing factors for TLS in this context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.